Swiss National Bank Myovant Sciences Ltd. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$24.03 - $27.02 $60,075 - $67,550	2,500 Added 2.46%	104,200 $2.81 Million
Q3 2022 Nov 09, 2022	BUY	$11.6 - $20.44 $24,360 - $42,924	2,100 Added 2.11%	101,700 $1.83 Million
Q2 2022 Aug 09, 2022	BUY	$7.78 - $14.69 $88,692 - $167,466	11,400 Added 12.93%	99,600 $1.24 Million
Q1 2022 May 09, 2022	BUY	$11.38 - $16.4 $83,074 - $119,719	7,300 Added 9.02%	88,200 $1.18 Million
Q3 2021 Nov 08, 2021	BUY	$18.94 - $26.99 $15,152 - $21,592	800 Added 1.0%	80,900 $1.82 Million
Q2 2021 Aug 06, 2021	SELL	$17.07 - $24.56 $46,089 - $66,312	-2,700 Reduced 3.26%	80,100 $1.82 Million
Q1 2021 May 07, 2021	BUY	$20.46 - $25.18 $26,598 - $32,734	1,300 Added 1.6%	82,800 $1.7 Million
Q3 2020 Nov 09, 2020	BUY	$14.05 - $22.6 $18,265 - $29,380	1,300 Added 1.62%	81,500 $1.15 Million
Q2 2020 Aug 05, 2020	BUY	$7.34 - $20.84 $14,680 - $41,680	2,000 Added 2.56%	80,200 $1.65 Million
Q1 2020 May 08, 2020	BUY	$6.55 - $14.76 $7,205 - $16,236	1,100 Added 1.43%	78,200 $590,000
Q4 2019 Feb 06, 2020	BUY	$4.2 - $19.21 $17,220 - $78,761	4,100 Added 5.62%	77,100 $1.2 Million
Q2 2019 Aug 02, 2019	BUY	$8.69 - $25.0 $363,242 - $1.05 Million	41,800 Added 133.97%	73,000 $661,000
Q1 2019 May 10, 2019	BUY	$16.83 - $24.45 $16,830 - $24,450	1,000 Added 3.31%	31,200 $745,000
Q4 2018 Feb 13, 2019	BUY	$15.01 - $25.2 $28,519 - $47,880	1,900 Added 6.71%	30,200 $496,000
Q1 2018 May 04, 2018	BUY	$12.46 - $21.32 $39,872 - $68,224	3,200 Added 12.75%	28,300 $602,000
Q3 2017 Nov 03, 2017	BUY	$9.93 - $15.47 $249,243 - $388,297	25,100	25,100 $388,000

Others Institutions Holding MYOV

# of Institutions

Shares Held

61.3K

Call Options Held

Put Options Held

View Full List

About Myovant Sciences Ltd.

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

More about MYOV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account